TISIDB

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF11616 WD repeat binding protein EZH2 PF00856 SET domain
Function	Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599). Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.

> Gene Ontology [ TOP ]
Biological Process	GO:0000082 G1/S transition of mitotic cell cycle GO:0000302 response to reactive oxygen species GO:0001837 epithelial to mesenchymal transition GO:0001889 liver development GO:0003012 muscle system process GO:0003299 muscle hypertrophy in response to stress GO:0003300 cardiac muscle hypertrophy GO:0006304 DNA modification GO:0006305 DNA alkylation GO:0006306 DNA methylation GO:0006354 DNA-templated transcription, elongation GO:0006368 transcription elongation from RNA polymerase II promoter GO:0006479 protein methylation GO:0006979 response to oxidative stress GO:0007346 regulation of mitotic cell cycle GO:0007623 circadian rhythm GO:0008213 protein alkylation GO:0008544 epidermis development GO:0009913 epidermal cell differentiation GO:0010035 response to inorganic substance GO:0010717 regulation of epithelial to mesenchymal transition GO:0010718 positive regulation of epithelial to mesenchymal transition GO:0010720 positive regulation of cell development GO:0010948 negative regulation of cell cycle process GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0014013 regulation of gliogenesis GO:0014834 skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration GO:0014887 cardiac muscle adaptation GO:0014888 striated muscle adaptation GO:0014896 muscle hypertrophy GO:0014897 striated muscle hypertrophy GO:0014898 cardiac muscle hypertrophy in response to stress GO:0016358 dendrite development GO:0016570 histone modification GO:0016571 histone methylation GO:0018022 peptidyl-lysine methylation GO:0018205 peptidyl-lysine modification GO:0021537 telencephalon development GO:0021543 pallium development GO:0021549 cerebellum development GO:0021695 cerebellar cortex development GO:0021761 limbic system development GO:0021766 hippocampus development GO:0022037 metencephalon development GO:0030522 intracellular receptor signaling pathway GO:0030856 regulation of epithelial cell differentiation GO:0030857 negative regulation of epithelial cell differentiation GO:0030900 forebrain development GO:0030902 hindbrain development GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0031346 positive regulation of cell projection organization GO:0032259 methylation GO:0032355 response to estradiol GO:0032784 regulation of DNA-templated transcription, elongation GO:0032785 negative regulation of DNA-templated transcription, elongation GO:0033674 positive regulation of kinase activity GO:0034243 regulation of transcription elongation from RNA polymerase II promoter GO:0034244 negative regulation of transcription elongation from RNA polymerase II promoter GO:0034502 protein localization to chromosome GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0034968 histone lysine methylation GO:0035983 response to trichostatin A GO:0035984 cellular response to trichostatin A GO:0036333 hepatocyte homeostasis GO:0040029 regulation of gene expression, epigenetic GO:0042063 gliogenesis GO:0042246 tissue regeneration GO:0042542 response to hydrogen peroxide GO:0042692 muscle cell differentiation GO:0042752 regulation of circadian rhythm GO:0043403 skeletal muscle tissue regeneration GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043414 macromolecule methylation GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0043500 muscle adaptation GO:0044728 DNA methylation or demethylation GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0045604 regulation of epidermal cell differentiation GO:0045605 negative regulation of epidermal cell differentiation GO:0045666 positive regulation of neuron differentiation GO:0045682 regulation of epidermis development GO:0045683 negative regulation of epidermis development GO:0045786 negative regulation of cell cycle GO:0045814 negative regulation of gene expression, epigenetic GO:0045860 positive regulation of protein kinase activity GO:0045930 negative regulation of mitotic cell cycle GO:0046677 response to antibiotic GO:0048384 retinoic acid receptor signaling pathway GO:0048385 regulation of retinoic acid receptor signaling pathway GO:0048387 negative regulation of retinoic acid receptor signaling pathway GO:0048511 rhythmic process GO:0048732 gland development GO:0048762 mesenchymal cell differentiation GO:0048872 homeostasis of number of cells GO:0050769 positive regulation of neurogenesis GO:0050773 regulation of dendrite development GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051146 striated muscle cell differentiation GO:0051147 regulation of muscle cell differentiation GO:0051148 negative regulation of muscle cell differentiation GO:0051153 regulation of striated muscle cell differentiation GO:0051154 negative regulation of striated muscle cell differentiation GO:0051962 positive regulation of nervous system development GO:0060485 mesenchyme development GO:0061008 hepaticobiliary system development GO:0070301 cellular response to hydrogen peroxide GO:0070314 G1 to G0 transition GO:0070734 histone H3-K27 methylation GO:0071168 protein localization to chromatin GO:0071236 cellular response to antibiotic GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0097421 liver regeneration GO:0098532 histone H3-K27 trimethylation GO:0098727 maintenance of cell number GO:1900006 positive regulation of dendrite development GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1904772 response to tetrachloromethane GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function	GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding GO:0003682 chromatin binding GO:0008168 methyltransferase activity GO:0008170 N-methyltransferase activity GO:0008276 protein methyltransferase activity GO:0008757 S-adenosylmethionine-dependent methyltransferase activity GO:0016278 lysine N-methyltransferase activity GO:0016279 protein-lysine N-methyltransferase activity GO:0016741 transferase activity, transferring one-carbon groups GO:0018024 histone-lysine N-methyltransferase activity GO:0031490 chromatin DNA binding GO:0042054 histone methyltransferase activity GO:0043021 ribonucleoprotein complex binding GO:0043566 structure-specific DNA binding GO:0046976 histone methyltransferase activity (H3-K27 specific) GO:0070878 primary miRNA binding GO:1990841 promoter-specific chromatin binding
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0031519 PcG protein complex GO:0034708 methyltransferase complex GO:0035097 histone methyltransferase complex GO:0035098 ESC/E(Z) complex GO:0044454 nuclear chromosome part GO:0045120 pronucleus

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00310 Lysine degradation
Reactome	R-HSA-5619507: Activation of HOX genes during differentiation R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-1266738: Developmental Biology R-HSA-212165: Epigenetic regulation of gene expression R-HSA-74160: Gene Expression R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-3214841: PKMTs methylate histone lysines R-HSA-212300: PRC2 methylates histones and DNA

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa00310 Lysine degradation

Reactome

R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-1266738: Developmental Biology
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-3214841: PKMTs methylate histone lysines
R-HSA-212300: PRC2 methylates histones and DNA

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EZH2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between EZH2 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26567139	Colon Carcinoma	Inhibit immunity (infiltration)	We found that PRC2 components and demethylase JMJD3-mediated histone H3 lysine 27 trimethylation (H3K27me3) repress the expression and subsequent production of Th1-type chemokines CXCL9 and CXCL10, mediators of effector T-cell trafficking. Moreover, the expression levels of PRC2 components, including EZH2, SUZ12, and EED, were inversely associated with those of CD4, CD8, and Th1-type chemokines in human colon cancer tissue, and this expression pattern was significantly associated with patient survival.
26523864	Ovarian Carcinoma	Promote immunity (T cell function)	EZH2 activated the Notch pathway by suppressing Notch repressors Numb and Fbxw7 via trimethylation of histone H3 at Lys27 and, consequently, stimulated T cell polyfunctional cytokine expression and promoted their survival via Bcl-2 signaling.
26503055	Ovarian Carcinoma	Inhibit immunity (infiltration)	Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment.
27505670	Diffuse Large B Cell Lymphoma	Inhibit immunity; immunotherapy target	Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.
29581297	hepatocellular carcinoma	Inhibit immunity (NK cell function); resistant to immunotherapy	The inhibition of EZH2 by small-molecule inhibitors or genetic means enhanced HCC cell eradication by NK cells in a NKG2D ligand-dependent manner.

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EZH2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EZH2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.303	0.291
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.034	0.982
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.505	0.672
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.475	0.167
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.398	0.827
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.578	0.813
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.052	0.889
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.311	0.831
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.388	0.785
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.398	0.651
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.473	0.706
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.445	0.000136

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EZH2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	5.5	1.9	0.66
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	5.1	2.3	0.647
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EZH2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EZH2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EZH2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EZH2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EZH2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EZH2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EZH2
Name	enhancer of zeste 2 polycomb repressive complex 2 subunit
Aliases	ENX-1; KMT6; KMT6A; enhancer of zeste (Drosophila) homolog 2; enhancer of zeste homolog 2 (Drosophila); ENX1 ......
Chromosomal Location	7q35-q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EZH2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EZH2